Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus

Mise à jour : Il y a 4 ans
Référence : U1111-1180-1213

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodiumglucose co-transporter-2 inhibitor monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes.


Critère d'inclusion

  • Diabetes Mellitus, Type 2

Liens